Related references
Note: Only part of the references are listed.Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets
Kathryn H. Ching et al.
MABS (2018)
Current progress in innovative engineered antibodies
William R. Strohl
PROTEIN & CELL (2018)
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Shuguang Tan et al.
PROTEIN & CELL (2018)
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
Zhenkun Na et al.
CELL RESEARCH (2017)
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
S. P. Koerner et al.
LEUKEMIA (2017)
Antibodies to watch in 2017
Janice M. Reichert
MABS (2017)
Immunoglobulin A: magic bullet or Trojan horse?
Marieke H. Heineke et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Biophysical properties of the clinical-stage antibody landscape
Tushar Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak et al.
STRUCTURE (2017)
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Babak Nami et al.
CANCERS (2017)
IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions
Chang-Han Lee et al.
NATURE IMMUNOLOGY (2017)
Hallmarks of response to immune checkpoint blockade
Alexandria P. Cogdill et al.
BRITISH JOURNAL OF CANCER (2017)
Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering
Xiaojie Yu et al.
BIODRUGS (2017)
State of the art in anti-cancer mAbs
S. M. Chiavenna et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals
G. R. Gunn et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Immunoglobulin Glycosylation Effects in Allergy and Immunity
Alexandra Epp et al.
CURRENT ALLERGY AND ASTHMA REPORTS (2016)
Harnessing Fc receptor biology in the design of therapeutic antibodies
Peter Sondermann et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Engineering antibody therapeutics
Mark L. Chiu et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2016)
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
Alessandra Fabi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2016)
Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity
Jenny Calow et al.
MABS (2016)
Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody
James R. Apgar et al.
MABS (2016)
Phage display-derived human antibodies in clinical development and therapy
Andre Frenzel et al.
MABS (2016)
A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
Erika Kovacs et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 84 (2015)
Mouse and human FcR effector functions
Pierre Bruhns et al.
IMMUNOLOGICAL REVIEWS (2015)
Macrophages are critical effectors of antibody therapies for cancer
Kipp Weiskopf et al.
MABS (2015)
Mechanisms of action of therapeutic antibodies for cancer
J. M. Redman et al.
MOLECULAR IMMUNOLOGY (2015)
Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1
Lai Sum Leoh et al.
MOLECULAR IMMUNOLOGY (2015)
Advances in Anticancer Immunotoxin Therapy
Christine Alewine et al.
ONCOLOGIST (2015)
Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies
Sue Townsend et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Automated analysis of high-throughput B-cell sequencing data reveals a high frequency of novel immunoglobulin V gene segment alleles
Daniel Gadala-Maria et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies
Masami Suzuki et al.
Journal of Toxicologic Pathology (2015)
Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions
Celine Monnet et al.
FRONTIERS IN IMMUNOLOGY (2015)
Therapeutic antibody engineering by high efficiency cell screening
Achim Doerner et al.
FEBS LETTERS (2014)
Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies
Zhi Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody
Celine Monnet et al.
MABS (2014)
Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery
E-Chiang Lee et al.
NATURE BIOTECHNOLOGY (2014)
Next-generation antibodies
James B. Evans et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Myeloid cells as effector cells for monoclonal antibody therapy of cancer
Rens Braster et al.
METHODS (2014)
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
Andrew J. Murphy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Complete Haplotype Sequence of the Human Immunoglobulin Heavy-Chain Variable, Diversity, and Joining Genes and Characterization of Allelic and Copy-Number Variation
Corey T. Watson et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2013)
A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
Gabriel J. Robbie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Nadia Harbeck et al.
BREAST CARE (2013)
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
Christian A. Gerdes et al.
CLINICAL CANCER RESEARCH (2013)
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Vibha Jawa et al.
CLINICAL IMMUNOLOGY (2013)
Human antibody expression in transgenic rats: Comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions
Biao Ma et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2013)
Response to: Monoclonal antibodies targeting CD20
Christian Klein et al.
MABS (2013)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein et al.
MABS (2013)
New checkpoint inhibitors ride the immunotherapy tsunami
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2013)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Natural and man-made V-gene repertoires for antibody discovery
William J. J. Finlay et al.
FRONTIERS IN IMMUNOLOGY (2012)
Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
Mareike Voigt et al.
NEOPLASIA (2012)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
HuCAL PLATINUM, a Synthetic Fab Library Optimized for Sequence Diversity and Superior Performance in Mammalian Expression Systems
Josef Prassler et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Craig Knox et al.
NUCLEIC ACIDS RESEARCH (2011)
Human monoclonal antibodies to HIV-1 gp140 from mice bearing YAC-based human immunoglobulin transloci
Sara Pruzina et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
Nigel M. Stapleton et al.
NATURE COMMUNICATIONS (2011)
Rapid Production of Recombinant Human IgG With Improved ADCC Effector Function in a Transient Expression System
Patrick H. C. van Berkel et al.
BIOTECHNOLOGY AND BIOENGINEERING (2010)
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
Marguerite Ghiotto et al.
INTERNATIONAL IMMUNOLOGY (2010)
Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions
Matthew J. Bernett et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Human Framework Adaptation of a Mouse Anti-Human IL-13 Antibody
Johan Fransson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
HAHA - nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology
Andreas Nechansky
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2010)
B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
Ronald Herbst et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky et al.
NATURE BIOTECHNOLOGY (2010)
Cross-Interaction Chromatography: A Rapid Method to Identify Highly Soluble Monoclonal Antibody Candidates
Steven A. Jacobs et al.
PHARMACEUTICAL RESEARCH (2010)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
Yik Andy Yeung et al.
JOURNAL OF IMMUNOLOGY (2009)
How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations
Eva-Maria Jahn et al.
NEW BIOTECHNOLOGY (2009)
Design of therapeutic proteins with enhanced stability
Naresh Chennamsetty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors
Elizabeth M. Bruckheimer et al.
NEOPLASIA (2009)
Fully human antibodies from transgenic mouse and phage display platforms
Nils Lonberg
CURRENT OPINION IN IMMUNOLOGY (2008)
Antibody-cytokine fusion proteins:: applications in cancer therapy
Elizabeth Ortiz-Sanchez et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Antibody diversification by somatic mutation: from Burnet onwards
Michael S. Neuberger
IMMUNOLOGY AND CELL BIOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Isolation of human monoclonal antibodies by mammalian cell display
Roger R. Beerli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
Shiqing Li et al.
STRUCTURE (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
Aya Jakobovits et al.
NATURE BIOTECHNOLOGY (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Structural basis for recognition of CD20 by therapeutic antibody rituximab
Jiamu Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy
Prashant Prabhat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
Julie A. McEarchern et al.
BLOOD (2007)
The impact of glycosylation on the biological function and structure of human immunoglobulins
James N. Arnold et al.
ANNUAL REVIEW OF IMMUNOLOGY (2007)
Humanized IgG(1) variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates
Amita Datta-Mannan et al.
DRUG METABOLISM AND DISPOSITION (2007)
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease
Stefka B. Petkova et al.
INTERNATIONAL IMMUNOLOGY (2006)
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
Kevin M. Cox et al.
NATURE BIOTECHNOLOGY (2006)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC
Yutaka Kanda et al.
BIOTECHNOLOGY AND BIOENGINEERING (2006)
Trends in antibody sequence changes during the somatic hypermutation process
Louis A. Clark et al.
JOURNAL OF IMMUNOLOGY (2006)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
CW Adams et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Modulation of therapeutic antibody effector functions by glycosylation engineering:: Influence of Golgi enzyme localization domain and co-expression of heterologous β1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II
C Ferrara et al.
BIOTECHNOLOGY AND BIOENGINEERING (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Optimization of humanized IgGs in glycoengineered Pichia pastoris
HJ Li et al.
NATURE BIOTECHNOLOGY (2006)
An engineered human IgG1 antibody with longer serum half-life
PR Hinton et al.
JOURNAL OF IMMUNOLOGY (2006)
B cell and antibody repertoire development in rabbits: The requirement of gut-associated lymphoid tissues
RG Mage et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2006)
Immunogenicity of engineered antibodies
WYK Hwang et al.
METHODS (2005)
Use of human germline genes in a CDR homology-based approach to antibody humanization
WYK Hwang et al.
METHODS (2005)
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
RJ Ober et al.
JOURNAL OF IMMUNOLOGY (2004)
Establishment of FUT8 knockout Chinese hamster ovary cells:: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity
N Yamane-Ohnuki et al.
BIOTECHNOLOGY AND BIOENGINEERING (2004)
Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA
K Mori et al.
BIOTECHNOLOGY AND BIOENGINEERING (2004)
Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level
RJ Ober et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics
SA Kellermann et al.
CURRENT OPINION IN BIOTECHNOLOGY (2002)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Radionuclide-antibody conjugates for single-cell cytotoxicity
MJ Mattes
CANCER (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Complement activation plays a key role in the side-effects of rituximab treatment
LE van der Kolk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies
RJ Ober et al.
INTERNATIONAL IMMUNOLOGY (2001)
Analysis of antibodies of known structure suggests a lack of correspondence between the residues in contact with the antigen and those modified by somatic hypermutation
MD Ramirez-Benitez et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2001)
Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design
EO Saphire et al.
SCIENCE (2001)
The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans
M Firan et al.
INTERNATIONAL IMMUNOLOGY (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Engineered antibodies with increased activity to recruit complement
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2001)
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
ET Boder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
